hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06369454 id: B7981090 briefTitle: A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-08-03 date: 2024-08-03 date: 2024-04-17 date: 2024-04-17 name: Pfizer class: INDUSTRY briefSummary: The purpose of this study is to learn about how different forms of the study medicine called ritlecitinib pass the intestines of healthy male adults when taken with or without food.
The study will take up to 3 months, including the screening period and follow-up phone call. Participants will have to stay at the study clinic for at least 11 days. There will be 3 periods in total, and a washout period of at least 3 days between dosings in Period 1 and Period 2, and at least 7 days between dosings in Period 2 and Period 3 for this study. On day 1 of each period, participants will take one form of Riltecitinib without food for the first two periods and with food for the last period. Participants will have blood samples taken both before and after taking ritlecitinib. A follow-up phone call will be made at 28 to 35 days after the last study period. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: BASIC_SCIENCE masking: NONE count: 12 type: ESTIMATED name: Ritlecitinib measure: Site of capsule disintegration and MR microsphere dispersion measure: Gastric emptying time measure: Small intestine residence/transit time measure: Colon arrival time measure: Colon (ascending, transverse, descending) residence/transit time measure: Total transit time measure: Maximum plasma concentration (Cmax) measure: Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf) measure: Area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration (AUClast) measure: Time for Cmax (Tmax) measure: Terminal half-life (t1/2) measure: Frequency of adverse events measure: Frequency of abnormal clinical laboratory tests measure: Frequency of abnormal vital signs measure: Frequency of abnormal 12-lead ECG sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06369441 id: Ovation-23-001 briefTitle: Collection of Biological Specimens and Associated Health Information overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2034-04 date: 2024-04-17 date: 2024-04-17 name: Ovation.io, Inc. class: INDUSTRY briefSummary: The purpose of this study is to collect blood samples from a large number of individuals with cancer to create a database for researchers to use in future studies. Researchers may use this database to discover new ways to detect and treat cancer and other diseases. Future studies may use stored blood samples to discover how genes affect health and disease. conditions: Cancer conditions: Other Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 10000 type: ESTIMATED measure: Biorepository sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ovation.io city: Portland state: Maine zip: 04101 country: United States name: Stephanie Balcaitis role: CONTACT phone: 617-795-4947 phoneExt: 2 email: ClinicalAffairs@ovation.io name: Ed Stepanski, PhD role: CONTACT email: ClinicalAffairs@ovation.io name: Pauline Gee, PhD role: PRINCIPAL_INVESTIGATOR lat: 43.66147 lon: -70.25533 hasResults: False
nctId: NCT06369415 id: 04/24/DD-BVMD briefTitle: Health of Babies Born From IVF Versus IVM at 5 Years Old acronym: FM-BABIES-5Y overallStatus: RECRUITING date: 2024-04-16 date: 2025-12-30 date: 2026-03-30 date: 2024-04-17 date: 2024-04-17 name: Mỹ Đức Hospital class: OTHER briefSummary: The investigators conduct a long-term follow-up at five years on offspring born from our randomized controlled trial (RCT) to investigate whether or not there is any difference in developmental outcomes in children born after capacitation IVM (CAPA IVM) compared with conventional IVF in order to give strong evidence about the safety of IVM in women with high antral follicle count. conditions: Infertility conditions: IVF conditions: IVM conditions: Development, Child studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 231 type: ESTIMATED name: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3 and behavioural screening according to Strength and Difficulties Questionnaires (SDQ's) measure: Normal ASQ-3 score rate. measure: Normal SDQ score rate. measure: Normal weight rate measure: Thinness rate measure: Overweight rate measure: Obesity rate measure: Score of Communication (ASQ-3 questionnaire) measure: Score of Gross motor (ASQ-3 questionnaire) measure: Score of Fine motor (ASQ-3 questionnaire) measure: Score of Problem solving (ASQ-3 questionnaire) measure: Score of Personal-Social (ASQ-3 questionnaire) measure: Score of Emotional symptoms (SDQ questionnaire) measure: Score of Conduct problems (SDQ questionnaire) measure: Score of hyperactivity/inattention (SDQ questionnaire) measure: Score of peer relationship problems (SDQ questionnaire) measure: Score of prosocial behavior (SDQ questionnaire) measure: The total difficulties score. sex: ALL minimumAge: 5 Years maximumAge: 5 Years stdAges: CHILD facility: Mỹ Đức Hospital status: RECRUITING city: Ho Chi Minh City state: Tan Binh country: Vietnam name: Tuong M Ho, MD, MCE role: CONTACT phone: +84903633377 email: tuongho.ivfmd@gmail.com lat: 10.82302 lon: 106.62965 hasResults: False
nctId: NCT06369402 id: 0963 briefTitle: Cognitive Impairment and Cerebral Haemodynamics in Individuals With Symptomatic Peripheral Arterial Disease acronym: CInCH PAD overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-02 date: 2025-02 date: 2024-04-17 date: 2024-04-25 name: University of Leicester class: OTHER name: University Hospitals, Leicester briefSummary: Background:
Twenty people with arterial disease of the legs causing pain while walking and twenty healthy people will have a series of non-invasive assessments. Arterial disease in the legs will be measured using ankle blood pressures before and after walking. Blood flow in the brain will be measured using ultrasound whilst performing memory and thinking tests. Results will be compared between the people with arterial disease in the legs and the healthy people to see if there are any differences in blood flow to the brain and memory and thinking.
This project will help determine if there is a link between arterial disease of the legs and memory and thinking problems caused by altered blood flow in the brain. It will enable future research in people with cognitive impairment caused by altered blood supply to the brain and to prevent confusion and further memory and thinking problems in people undergoing surgery for arterial disease of the legs. conditions: Peripheral Arterial Disease conditions: Cognitive Impairment studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 40 type: ESTIMATED name: Cerebral haemodynamic testing using transcranial Doppler name: Ankle-brachial pressure index name: Six-minute walk test measure: Peak % change of CBv from baseline measure: Autoregulation index (Tieck's model) measure: Absolute score achieved on the Addenboook's cognitive examination (III) measure: Digit span forward and backward scores measure: Claudication distance measure: Maximal walking distance measure: Ankle-brachial pressure index sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Glenfield Hospital Leicester city: Leicester state: Leicestershire zip: LE3 9QP country: United Kingdom lat: 52.6386 lon: -1.13169 hasResults: False
nctId: NCT06369389 id: RC31/23-0417 briefTitle: Real-life Management of Patients Eligible for CAR-T Cell Therapy acronym: CARAVAGE overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2033-12-31 date: 2034-12-31 date: 2024-04-17 date: 2024-04-17 name: University Hospital, Toulouse class: OTHER name: Ligue contre le cancer, France name: Janssen, LP briefSummary: Adoptive immunotherapy using CAR-T cells is now one of the Advanced Therapy Medicines routinely used for relapsed or refractory lymphoid hemopathies. In 2023, in France, 5 types of CAR-T cells have marketing authorization for 6 different indications. However, these marketing authorizations are based on clinical trials involving a limited number of selected patients. Real-life data are essential for assessing the post-authorization use of these innovative treatments. The French national DESCAR-T registry, promoted by LYSARC and in which Toulouse University Hospital plays an active role, is an international reference for this real-life evaluation. It does not, however, allow precise evaluation of patient-centered indicators and care pathways.
With the increasing number of indications and candidate patients, Toulouse University Hospital, the only healthcare facility authorized in the Western Occitanie region to administer CAR-T cells, is faced with growing hospital needs and longer treatment times. In 2023, this has necessitated the implementation of new ambulatory and inter-facility care pathways in collaboration with the referral centers of the Onco-Occitanie Ouest regional cancer network. The selection of patients for CAR-T cell treatment is based on objective clinical criteria linked to the pathology (histology, morphological localization, size and kinetics of the tumor mass) and the patient (physiological age, performance index, comorbidities, patient choice). Because of their innovative nature, in a difficult psychological and physical context for the patient (refractory disease), CAR-T cell care pathways also need to be evaluated in terms of their "quality of life" dimension. The impact of non-biological determinants (also described as social and territorial inequalities in health) such as place of residence and distance from healthcare provision, marital, economic and social status, has never been explored on the accessibility and progress of the CAR-T cell treatment pathway.
The creation of a registry of patients eligible for CAR-T cells at Toulouse University Hospital will enable these lines of research to be explored on the scale of a region with a population of 3 million. conditions: Hemopathy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 550 type: ESTIMATED name: Patients eligible for CAR-T treatment measure: Overall survival of patients with hemopathy eligible for CAR-T cell therapy measure: Compare progression-free survival and overall survival of patients according to care pathway and type of hemopathy, and investigate clinical and socioeconomic factors associated with better survival measure: Evaluate the time taken to treat patients with CAR-T cells sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Toulouse city: Toulouse state: CHU De Toulouse zip: 31059 country: France name: Pierre BORIES, MD role: CONTACT phone: 0531156415 phoneExt: 33 email: bories.pierre@iuct-oncopole.fr name: Sandra DE BARROS role: CONTACT phone: 0561145982 email: debarros.s@chu-toulouse.fr lat: 43.60426 lon: 1.44367 hasResults: False
nctId: NCT06369376 id: ONZ-2022-0072 briefTitle: Electrodiagnostic Approach for Pectoral Nerve Conduction Studies overallStatus: COMPLETED date: 2023-06-30 date: 2023-11-29 date: 2024-04-12 date: 2024-04-17 date: 2024-04-17 name: University Hospital, Ghent class: OTHER briefSummary: Anatomical studies have challenged traditional perceptions of the pectoral nerve structure, revealing a network of three branches rather than the previously accepted medial and lateral branches. This study aims to explore the implications of this updated anatomy on nerve conduction studies of the pectoral nerve and proposes a modified nerve conduction study protocol to enhance diagnostic accuracy.
A study on 25 volunteers was conducted, examining the three parts of the pectoral nerve. Electrode placement followed a detailed methodology ensuring precise data collection. The nerve conduction study was performed bilaterally, exploring latency and amplitude while addressing inter-observer variability and demographic influences. conditions: New Nerve Conduction Protocol for Pectoral Nerve studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 25 type: ACTUAL name: New nerve conduction protocol measure: Latency measure: Amplitude sex: ALL minimumAge: 22 Years maximumAge: 68 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UZ Gent city: Gent state: Oost-Vlaanderen zip: 9000 country: Belgium lat: 51.05 lon: 3.71667 hasResults: False
nctId: NCT06369363 id: STUDY000024245 briefTitle: Estrogen Deficiency on Cardiovascular Risk overallStatus: NOT_YET_RECRUITING date: 2025-09 date: 2027-09 date: 2027-11 date: 2024-04-17 date: 2024-04-17 name: Milton S. Hershey Medical Center class: OTHER briefSummary: To explore how estrogen deficiency impacts the blood pressure (BP) and sympathetic nerve activity (SNA), and how it impacts the production of the key pro-inflammatory mediators such as Tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). It is hypothesized that estrogen deficiency increases BP, SNA and the pathway activities of the key pro-inflammatory mediators. Those effects are impacted through the downregulation of the estrogen receptor. conditions: Postmenopausal Symptoms conditions: Cardiovascular Diseases studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Placebo name: Estradiol measure: Red blood cell flux measure: Mean arterial pressure (mmHg) measure: baseline plasma TNF-α concentration (pg/ml) measure: One week post-intervention plasma TNF-α concentration (pg/ml) measure: baseline plasma IL-1β concentration (pg/ml) measure: One week post-intervention plasma IL-1β concentration (pg/ml) measure: baseline plasma IL-6 concentration (pg/ml) measure: One week post-intervention plasma IL-6 concentration (pg/ml) measure: baseline plasma estrogen (pg/ml) measure: One week post-intervention plasma estrogen (pg/ml) sex: FEMALE minimumAge: 54 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06369350 id: STUDY000020217 id: 940567 type: OTHER_GRANT domain: American Heart Association briefTitle: Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2025-09 date: 2025-09 date: 2024-04-17 date: 2024-04-17 name: Milton S. Hershey Medical Center class: OTHER name: American Heart Association briefSummary: In this study, we are trying to see if vitamin B6 can minimize the amplified blood pressure response to exercise following ischemia-reperfusion injury. We are interested in a protein called P2X3, of which function can be blocked by vitamin B6, in the neurons of our nervous system. It is very important for blood pressure regulation. We would like to see if the P2X3 plays a role in patients' rising blood pressure during exercise. The results of the proposed studies will provide a base for those two potential economic and non-invasive inventions to improve the overall health and well-being of PAD patients. conditions: Ischemia Reperfusion Injury conditions: Peripheral Artery Disease studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Vitamin B6 25 MG name: Vitamin B6 50 MG name: Vitamin B6 100 MG name: Placebo measure: baseline blood pressure in mmHg measure: Second visit blood pressure in mmHg measure: baseline heart Rate in beats per minute measure: Second visit heart Rate in beats per minute measure: baseline muscle sympathetic nerve activity in burst/min measure: Second visit muscle sympathetic nerve activity in burst/min measure: baseline walking time in minutes measure: Second visit walking time in minutes sex: ALL minimumAge: 21 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06369337 id: 014-24 briefTitle: Ultrasound Study of the Submentonian Musculature and Its Relationship in Dysphagia overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2025-06 date: 2024-04-17 date: 2024-04-22 name: Universidad Europea de Madrid class: OTHER name: Hospital Universitario Ramon y Cajal briefSummary: Acquired dysphagia is one of the most frequent complications suffered by patients in intensive care units (ICU) after orotracheal extubation. Ultrasound has proven to be a useful method in the morphological and kinematic exploration of the main swallowing structures. AIM: to evaluate, through ultrasound procedures, the evolution of the morphology of the tongue and muscles of the floor of the mouth and the hyolaryngeal kinematics in patients intubated \>48h and to correlate these measurements with the possible development of acquired dysphagia. The incidence of dysphagia and ICU acquired weakness (ICUAW) in subjects with \>48h of intubation and the relative risk factors associated with baseline characteristics and clinical variables will be described. METHODOLOGY: Design: Single-center cohort study (Ramón y Cajal University Hospital). Participants: subjects \>18 years old, admitted to an intensive care unit (ICU), with \>48 hours of orotracheal intubation who meet eligibility criteria. Outcomes: the study of socio-demographic and clinical variables related to ICU admission will be included. The physical function variables will be analyzed through the Medical Research Council (MRC) and Functional Status Score (FSS), as well as swallowing function variables through the Volume-Viscosity Swallow (VVS-T) and Functional Oral Intake Scale scales. (FOIS) and Gugging Swallowing Screen (GUSS). Measurements will be made of the thickness and echogenicity of the submental and tongue muscles, as well as hyolaryngeal kinematics conditions: Dysphagia, Oropharyngeal conditions: Deglutition Disorders conditions: Mechanical Ventilation Complication studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Ultrasound measure: Thickness of the submental muscles measure: Hyolaryngeal displacement measure: Muscle strength measure: Functional Status measure: Swallowing function measure: Swallowing function measure: Swallowing function sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06369324 id: 05 briefTitle: Efficacy of Pain Neuroscience Education and Physiotherapy in Patients Diagnosed With Spondyloarthritis overallStatus: RECRUITING date: 2024-02-15 date: 2024-04-11 date: 2024-04-11 date: 2024-04-17 date: 2024-04-18 name: Universidad de Extremadura class: OTHER briefSummary: Spondyloarthritis, notably ankylosing spondylitis (AS), represents a chronic rheumatic condition typified by persistent back pain and stiffness. It constitutes a substantial portion of diagnoses within rheumatology units and exhibits a higher prevalence among males. Diagnosis relies upon comprehensive clinical evaluation, including patient history, physical examination, and adjunctive radiological assessments, with genetic predisposition, particularly the presence of the HLA-B27 antigen, playing a significant role.
The evolving landscape of spondyloarthritis management underscores the necessity of further research into multimodal treatment approaches, particularly in integrating novel interventions such as electrophysical agents. By elucidating the mechanisms of action and exploring their synergistic effects, clinicians can refine treatment protocols and ultimately enhance the quality of care provided to individuals living with spondyloarthritis. conditions: Spondyloarthropathies conditions: Ankylosing Spondylitis conditions: Exercise Therapy conditions: Physical Therapy Modalities conditions: Pain Management studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Pain education name: Exercise supervised by external focus name: Therapy by means of electrical stimulation (electro-massage) measure: Numeric Pain Rating Scale (NPRS) measure: Cervical and Lumbar Joint Position Sense Error measure: Cervical Range of Motion (CRoM) measure: Pressure Pain Threshold (PPT) measure: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) measure: Bath Ankylosing Spondylitis Motility Index (BASMI) measure: Bath Ankylosing Spondylitis Functional Index (BASFI). measure: Kinesophobia measure: Catastrophizing Pain measure: Fear-Avoidance Beliefs Questionnaire (FABQ) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Medicine and Health Sciences status: RECRUITING city: Badajoz zip: 06006 country: Spain name: Carlos Fernández-Morales, MSc role: CONTACT lat: 38.87789 lon: -6.97061 hasResults: False
nctId: NCT06369298 id: JK07.2.01 briefTitle: Study of JK07 in Patients With Chronic Heart Failure acronym: RENEU-HF overallStatus: RECRUITING date: 2024-03-28 date: 2025-12-31 date: 2026-06-30 date: 2024-04-16 date: 2024-04-18 name: Salubris Biotherapeutics Inc class: INDUSTRY briefSummary: This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
Participants in both cohorts will be randomized into either low dose JK07, high dose JK07 or placebo. Participants will have a 2:1 chance of receiving JK07 versus placebo. conditions: Heart Failure With Reduced Ejection Fraction conditions: Heart Failure With Preserved Ejection Fraction studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 282 type: ESTIMATED name: JK07 name: Placebo measure: Safety - Cohort 1 measure: Efficacy - Cohort 1 measure: Safety - Cohort 2 sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Southern California Heart Specialists status: RECRUITING city: Pasadena state: California zip: 91105 country: United States name: Gregory Giesler role: CONTACT lat: 34.14778 lon: -118.14452 facility: New Generation of Medical Research status: RECRUITING city: Hialeah state: Florida zip: 33016 country: United States name: Karelia Ruiz role: CONTACT lat: 25.8576 lon: -80.27811 facility: Louisiana Heart Center status: RECRUITING city: Covington state: Louisiana zip: 70433 country: United States name: Bruce Iteld, MD role: CONTACT lat: 30.47549 lon: -90.10042 facility: Cardiology and Vascular Associates status: RECRUITING city: Bloomfield Hills state: Michigan zip: 48304 country: United States name: Kirit Patel role: CONTACT lat: 42.58364 lon: -83.24549 facility: St. Louis Heart and Vascular Cardiology status: RECRUITING city: Saint Louis state: Missouri zip: 63136 country: United States name: Harvey Serota role: CONTACT lat: 38.62727 lon: -90.19789 facility: Southwest Family Medicine status: RECRUITING city: Dallas state: Texas zip: 75235 country: United States name: Chriistte Dharma role: CONTACT lat: 32.78306 lon: -96.80667 hasResults: False